INMB — Inmune Bio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1711754 ·
Last close
$1.24
Market Cap
$32.97M
52W High
$1.79
52W Low
$1.09
ADV30
444,560
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,812,000 | -5,407,000 | 25,818,000 | 21,358,000 | 6,194,000 |
| Dec 2025 | 0 | — | -5,474,000 | -5,264,000 | 32,351,000 | 24,751,000 | 8,827,000 |
| Sep 2025 | 0 | — | -7,433,000 | -6,472,000 | 33,358,000 | 27,734,000 | 7,980,000 |
| Jun 2025 | 0 | — | -8,057,000 | -24,458,000 | 37,684,000 | 33,374,000 | 8,817,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,582,000
Investing CF
$-336,000
Financing CF
$27,612,000
CapEx
$-336,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.32
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-209,037,000
Inventory
—
Receivables
$4,541,000
ST Investments
—
EBIT TTM
$-30,869,000
Pretax Income TTM
$-45,933,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
—
Free Cash Flow
$-11,248,000
Enterprise Value
$13,117,720
Total Cash
$21,358,000
Total Debt
$1,510,000
Shares Out
26,585,258
Trailing EPS
$-1.63
Book Value
$0.74
ROE
-168.8%
ROA
-52.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 50,000 | -30,869,000 | -45,933,000 | 32,351,000 | 8,827,000 | — | -22,582,000 |
| Dec 2024 | 14,000 | -42,635,000 | -42,082,000 | 39,562,000 | 7,465,000 | — | -33,361,000 |
| Dec 2023 | 155,000 | -29,741,000 | -30,008,000 | 57,001,000 | 18,862,000 | — | -11,980,000 |
| Dec 2022 | 374,000 | -25,951,000 | -27,299,000 | 81,795,000 | 21,691,000 | — | -22,686,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.53
Max Pain — expiry 2026-06-18
max pain strike: $1.50 · spot: $1.28 · call oi: 2,903 · put oi: 10
Expected Move to 2026-06-18:
±$0.42
(32.81%) —
implied range
$0.86 –
$1.70
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRML | Greenland Mines Ltd | $35.52M | $0.29 | — |
| EVAX | Evaxion A/S | $30.36M | $3.64 | — |
| SNTI | Senti Biosciences Holdings, Inc. | $29.90M | $0.96 | — |
| ALGS | Aligos Therapeutics, Inc. | $28.45M | $5.28 | — |
| ENZN | Viskase Holdings, Inc. | $38.35M | $5.80 | — |
News headlines (Yahoo Finance, 1h cache)
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
2026-06-02 12:00 · Yahoo
INmune Bio (INMB) Q4 2025 Earnings Transcript
2026-06-01 21:15 · Yahoo
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
2026-05-15 12:00 · Yahoo
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
2026-05-14 12:00 · Yahoo
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
2026-05-13 12:00 · Yahoo
INmune Bio (INMB) Q1 2026 Earnings Transcript
2026-05-08 14:30 · Yahoo
INmune Bio, Inc. Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
2026-05-07 20:00 · Yahoo
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
2026-05-05 20:00 · Yahoo
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
2026-04-30 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.